Your browser doesn't support javascript.
loading
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.
Antill, Yoland; Kok, Peey-Sei; Robledo, Kristy; Yip, Sonia; Cummins, Michelle; Smith, Deborah; Spurdle, Amanda; Barnes, Elizabeth; Lee, Yeh Chen; Friedlander, Michael; Baron-Hay, Sally; Shannon, Catherine; Coward, Jermaine; Beale, Philip; Goss, Geraldine; Meniawy, Tarek; Lombard, Janine; Andrews, John; Stockler, Martin R; Mileshkin, Linda.
Afiliação
  • Antill Y; Medical Oncology, Cabrini Health, Malvern, Victoria, Australia Yoland.Antill@monash.edu.
  • Kok PS; Faculty of Medicine, Dentistry and Health Sciences, Monash University, Clayton, VIC, Australia.
  • Robledo K; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
  • Yip S; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
  • Cummins M; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
  • Smith D; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
  • Spurdle A; Mater Pathology, Mater Research and University of Queensland, Brisbane, Queensland, Australia.
  • Barnes E; Molecular Cancer Epidemiology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
  • Lee YC; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
  • Friedlander M; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
  • Baron-Hay S; Department of Medical Oncology, Prince of Wales Hospital Nelune Comprehensive Cancer Centre, Randwick, New South Wales, Australia.
  • Shannon C; Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.
  • Coward J; Department of Medical Oncology, Prince of Wales Hospital Nelune Comprehensive Cancer Centre, Randwick, New South Wales, Australia.
  • Beale P; Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
  • Goss G; Mater Cancer Care Centre, Mater Hospital, South Brisbane, Queensland, Australia.
  • Meniawy T; Clinical Trials Unit, Icon Cancer Care, South Brisbane, Queensland, Australia.
  • Lombard J; School of Medicine, University of Queensland, St Lucia, QLD, Australia.
  • Andrews J; Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.
  • Stockler MR; Medical Oncology, Monash Medical Centre Clayton, Clayton, Victoria, Australia.
  • Mileshkin L; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
J Immunother Cancer ; 9(6)2021 06.
Article em En | MEDLINE | ID: mdl-34103352
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Endométrio / Antineoplásicos Imunológicos / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Endométrio / Antineoplásicos Imunológicos / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália